Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
3/25/2021
0:00
17:39
Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
More episodes from "JAMA Oncology Author Interviews"
Don't miss an episode of “JAMA Oncology Author Interviews” and subscribe to it in the GetPodcast app.
